Literature DB >> 12445379

The molecular basis for prevention of colorectal cancer.

W F Krause1, R N DuBois.   

Abstract

Colorectal cancer is the second leading cause of cancer death in the United States. Despite aggressive treatment and early screening strategies, the prognosis for patients with advanced disease remains poor. Extensive research examining familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC), two common forms of inherited colorectal cancer, have provided invaluable insights into some of the molecular mechanisms underlying both familial, as well as nonfamilial, colorectal cancer. The molecules involved in these pathways may provide effective targets for prevention and/or treatment of colorectal cancer. These targets include cyclooxygenase-2 (COX-2), peroxisome proliferator-activated receptor (PPAR)-delta, PPAR-gamma, transforming growth factor-beta receptor type II, epidermal growth factor receptor, and inducible-nitrous oxide synthase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12445379     DOI: 10.3816/CCC.2001.n.005

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  3 in total

1.  Prophylactic and therapeutic benefits of COX-2 inhibitor on motility dysfunction in bowel obstruction: roles of PGE₂ and EP receptors.

Authors:  You-Min Lin; Sushil K Sarna; Xuan-Zheng Shi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-28       Impact factor: 4.052

2.  Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction.

Authors:  S R Zamuner; N Warrier; A G Buret; W K MacNaughton; J L Wallace
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

3.  Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate.

Authors:  C M Mounier; D Wendum; E Greenspan; J-F Fléjou; D W Rosenberg; G Lambeau
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.